ChinaAMC CSI All Share Health Care Devices ETF

Mindray released FY2026 Q1 earnings on April 28 During-Market (BJT), actual revenue CNY 8.352 B (forecast CNY 8.382 B), actual EPS CNY 1.9224 (forecast CNY 1.7195)

United Imaging Healthcare released FY2026 Q1 earnings on April 28 Pre-Market (BJT), actual revenue CNY 2.908 B (forecast CNY 3.045 B), actual EPS CNY 0.48 (forecast CNY 0.5586)

Furui Co., Ltd. released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 360.14 M, actual EPS CNY 0.12

Snibe released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 1.129 B (forecast CNY 1.193 B), actual EPS CNY 0.5625 (forecast CNY 0.5609)

Snibe released FY2025 Annual Earnings on April 27 Pre-Market (BJT), actual revenue CNY 4.577 B (forecast CNY 4.701 B), actual EPS CNY 2.0621 (forecast CNY 2.1398)

Snibe released FY2025 Q4 earnings on April 27 Pre-Market (BJT), actual revenue CNY 1.149 B (forecast CNY 1.223 B), actual EPS CNY 0.5286 (forecast CNY 0.5662)

BGI Genomics released FY2025 Q4 earnings on April 24 (BJT), actual revenue CNY 1.032 B, actual EPS CNY -1.4274

BGI Genomics released FY2025 earnings on April 24 (BJT), actual revenue CNY 3.705 B (forecast CNY 3.604 B), actual EPS CNY -1.4812 (forecast CNY 0.06)

YUYUE MEDICAL released FY2025 Q4 earnings on April 24 Pre-Market (BJT), actual revenue CNY 1.41 B (forecast CNY 1.868 B), actual EPS CNY 0.0155 (forecast CNY 0.2231)

BGI Genomics released FY2026 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 808.65 M, actual EPS CNY -0.0229

YUYUE MEDICAL released FY2025 earnings on April 24 Pre-Market (BJT), actual revenue CNY 7.955 B (forecast CNY 8.462 B), actual EPS CNY 1.48 (forecast CNY 1.9106)

Yuyue Medical released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 2.37 B (forecast CNY 2.704 B), actual EPS CNY 0.4291 (forecast CNY 0.4778)

INTCO released FY2026 Q1 earnings on April 23 During-Market (BJT), actual revenue CNY 2.887 B, actual EPS CNY 0.02

Lepu Medical released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 1.544 B (forecast CNY 1.673 B), actual EPS CNY -0.0108 (forecast CNY 0.0694)

APT released FY2026 Q1 earnings on April 23 During-Market (BJT), actual revenue CNY 704.08 M (forecast CNY 718.77 M), actual EPS CNY 1.63 (forecast CNY 1.567)

Lepu Medical released FY2025 earnings on April 23 After-Market (BJT), actual revenue CNY 6.483 B (forecast CNY 6.635 B), actual EPS CNY 0.5219 (forecast CNY 0.5912)

INTCO released FY2025 Annual Earnings on April 23 After-Market (BJT), actual revenue CNY 9.926 B (forecast CNY 10.06 B), actual EPS CNY 1.57 (forecast CNY 2.035)

INTCO released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 2.501 B, actual EPS CNY 0.1302

Mindray to release FY2026 Q1 earnings report on April 29 During-Market BJT, forecast revenue CNY 8.382 B, EPS CNY 1.7242

United Imaging Healthcare to Release FY2026 Q1 Earnings on April 29 Pre-Market (BJT), Forecast Revenue CNY 3.045 B, EPS CNY 0.5586

588130

159898

512290

562600

510660

A new therapeutic approach for atopic dermatitis is being developed, utilizing a dual mechanism that targets barrier repair through KLK5/7 and inflammation inhibition through IL-13. This first-in-class treatment aims to address the needs of patients with atopic dermatitis. A Phase 2 patient proof-of-concept study focusing on moderate-to-severe cases of atopic dermatitis is planned to commence soon. This study will test the effectiveness of the treatment and its potential benefits for patients.

Unusual Whales

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Guotai CSI Bio-medicine ETF

iShares US Medical Devices

ChinaAMC SSE Health Care ETF Initiating Fund

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

159883

Broncus Holding Corp. announced that all resolutions at its May 14, 2026 AGM were approved by shareholders. This includes the approval of the 2025 audited financial statements, reappointment of Ernst & Young as auditor, and mandates for share issuance and buybacks. Shareholders also re-elected two non-executive directors, with varying support levels. A special resolution to amend the articles of association was also passed, enhancing the board's flexibility in capital management and governance. Broncus is a Cayman Islands-based medical company listed in Hong Kong, focusing on healthcare technologies.

Tip Ranks

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

BRONCUS-B

Broncus shareholders back all AGM resolutions, update articles of association

516930

InventHelp has announced a new line of medical wear designed to protect healthcare workers from electromagnetic radiation emitted by medical equipment. The patent-pending invention, known as MEDICAL ATTIRE, deflects electromagnetic fields, enhancing safety and providing peace of mind. The clothing is stylish, easy to wear, and is currently available for licensing or sale to manufacturers or marketers. For more information, interested parties can contact InventHelp directly.

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC CSI Biotechnology Theme ETF

InventHelp Inventor Develops Medical Wear to Protect Against EMFs (SBT-2240)

512170

513060

Boule Diagnostics AB's 2026 AGM approved the 2025 financial statements, decided to retain earnings without a dividend, and granted discharge from liability to the board and CEO. The existing board structure was reaffirmed, reappointing all five directors, including chairman Torben Jørgensen. Shareholders renewed key authorizations for issuing new shares and managing the company's own shares, enhancing Boule's financial flexibility for future capital raising and strategic options. Boule Diagnostics operates in decentralized hematology and diagnostic solutions globally, with a market cap of SEK125.4M.

SPDR S&P Health Equip

Hwabao WP CSI Medical Service ETF

Bosera Hang Seng Health Care ETF(QDII)

Boule Diagnostics AGM Retains Earnings, Renews Board Mandates

560600

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ark Genomic Revolution ETF

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Novo Nordisk A/S (B Shares) ADRhedged

iShares Global Healthcare

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition

02170

Suzhou Basecare Medical Corp. Ltd. has received NMPA Class III approval for its Gems cleavage embryo culture medium, enhancing its portfolio of certified products. This medium, developed with expertise from the Sydney IVF Center, aims to improve embryo stress resistance and support in assisted reproduction. With this approval, all four core products in the Gems series are now certified, creating a comprehensive embryo culture system for fertility specialists. The company focuses on assisted reproductive technologies and has a market cap of HK$506M.

BASECARE-B

Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium

Dotmatics has launched Luma Agent, an AI co-scientist integrated into the Luma Scientific Intelligence Platform. This agentic AI can plan and execute complex scientific tasks using natural language, manage workflows, and analyze data, all while ensuring traceability and reproducibility. Unlike general-purpose AI, Luma Agent operates on structured scientific data, allowing scientists to configure the platform and complete tasks in minutes rather than days. Designed to meet governance standards, Luma Agent logs every action and requires human approval for data changes, enhancing safety and accountability in scientific research.

prnewswire

iShares US Healthcare Providers

BlackRock, Inc.

SPDR S&P Health

VG Health

Gartner

07:05 ETDotmatics introduces Luma Agent: the AI co-scientist built on structured scientific data

ONWARD Medical Announces Results of the 2026 Annual General Meeting of Shareholders | ONWRY Stock News

StockTitan

ONWARD Medical Announces Results of the 2026 Annual General Meeting of Shareholders | ONWRY Stock News

Imaging Biometrics Limited has corrected an error regarding its proposed share sub-division ahead of the Annual General Meeting on June 3, 2026. Each ordinary share of £0.01 will now be sub-divided into one ordinary share of £0.005, with the total shares remaining at 246,709,789. The AGM resolutions remain unaffected, and updated documentation will be available on the company’s website. Spark’s AI Analyst rates IBAI stock as Neutral, citing weak financial performance and bearish technicals, despite low leverage reducing balance-sheet risk.

E Fund CSI Biotechnology Theme ETF

VanEck Biotech ETF

China Merchants CSI Biotechnology Theme ETF

GE HealthCare Tech

Imaging Biometrics Corrects AGM Share Sub-division Terms Ahead of June Meeting

300347

Shanghai-based Immunocan has successfully closed a RMB250 million Series A funding round, led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The funds will be utilized to enhance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, develop an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan specializes in antibody discovery using gene-editing technologies and collaborates with various pharmaceutical companies globally.

ChinaAMC CSI All Share Health Care Devices ETF(562600.SH)

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

Broncus shareholders back all AGM resolutions, update articles of association

InventHelp Inventor Develops Medical Wear to Protect Against EMFs (SBT-2240)

Boule Diagnostics AGM Retains Earnings, Renews Board Mandates

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition